Pricing Log in Create free account

CytomX Therapeutics, Inc. (CTMX) vs DiaMedica Therapeutics, Inc. (DMAC)

CytomX Therapeutics, Inc. and DiaMedica Therapeutics, Inc. are both Biotechnology companies. CytomX Therapeutics, Inc. and DiaMedica Therapeutics, Inc. are of similar size ($487.5M and $466.3M). DiaMedica Therapeutics, Inc. has the higher net margin (0.00% vs −630.4%) and the higher return on invested capital (0.00% vs −20.8%). Across the 13 metrics below, DiaMedica Therapeutics, Inc. leads on 8 and CytomX Therapeutics, Inc. on 5.

Valuation

Metric CTMX DMAC Biotechnology median
P/E n/m n/m 10.60
P/S 34.21 n/m 9.40
P/B 1.68 13.30 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 10.89 n/m 9.02
Earnings yield (22.83%) (7.61%) (32.88%)
Free cash flow yield (10.61%) (6.19%) (23.13%)

Profitability

Metric CTMX DMAC Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (676.45%) 0.00% 0.00%
Net margin (630.38%) 0.00% 0.00%
Free cash flow margin (362.89%) 0.00% 0.00%
Return on equity (45.08%) (114.62%) (51.96%)
Return on assets (33.82%) (98.18%) (46.06%)
Return on invested capital (20.82%) 0.00% 0.00%

Growth

Metric CTMX DMAC Biotechnology median
Revenue growth (TTM) (87.66%) — 6.76%
EPS growth (last fiscal year) (139.47%) (16.67%) 29.88%
Revenue growth, 5-year CAGR (5.36%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CTMX DMAC Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.82 6.72 4.97
Net debt to EBITDA 5.91 1.70 1.01

Dividend

Metric CTMX DMAC Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CTMX DMAC Biotechnology median
Market cap 466.30m 487.49m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack